More tools:Markets·Screener·Research·Chat

Cytokinetics Inc. (CYTK) Financial Statements

Cytokinetics Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SGMVF2
XNAS · usd
73.97▼ 1.38 (-1.83%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close75.35
Day's Range72.39 – 76.81
52-Week Range47.22 – 88.31
Volume1.9M
Avg Volume1.9M
Share Statistics
Shares Outstanding
Employees673
ExchangeXNAS
Listed2004-04-29
Share count as of August 4, 2026
Loading Income Statement…
Key questions about Cytokinetics Inc. (CYTK)
What is Cytokinetics Inc.'s Market Cap?
Cytokinetics Inc.'s Market Cap is $10.3B, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s Enterprise Value?
Cytokinetics Inc.'s Enterprise Value is $10.3B, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s Price / Sales?
Cytokinetics Inc.'s Price / Sales is 152.0×, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s EV / Revenue?
Cytokinetics Inc.'s EV / Revenue is 152.3×, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s EV / EBITDA?
Cytokinetics Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s Revenue (TTM)?
Cytokinetics Inc.'s Revenue (TTM) is $67.7M, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s Net Income (TTM)?
Cytokinetics Inc.'s Net Income (TTM) is -$894.0M, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s EBITDA?
Cytokinetics Inc.'s EBITDA is -$695.4M, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s Diluted EPS (TTM)?
Cytokinetics Inc.'s Diluted EPS (TTM) is -6.43, based on as-reported figures from SEC (XBRL) filings.
What is Cytokinetics Inc.'s EBITDA Margin?
Cytokinetics Inc.'s EBITDA Margin is -1027.6%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues——
YoY growth-57.1%+1125.8%——
Operating expenses:
Research and development
Selling, general and administrative——
Cost of goods sold——
Collaboration cost of sales——
Total operating expenses
% of revenue726.0%1048.7%——
Operating loss
% of revenue-626.0%-948.7%——
Interest and other expense, net——
Non-cash interest expense on liabilities related to revenue participation right purchase agreements
Interest and other income, net
Change in fair value of derivative liabilities
Change in fair value of liabilities related to RPI Transactions
Net loss
% of revenue-694.4%-1064.5%——
Net loss per share - basic—
Net loss per share - diluted—